Novel Cryoballoon Technology for Atrial Fibrillation Ablation: Impact of Pulmonary Vein Variant Anatomy, Cooling Characteristics and 1-Year Outcome from the CHARISMA Registry
Marco Schiavone,Stefano Bianchi,Maurizio Malacrida,Gaetano Fassini,Riccardo Ricciolino,Domenico Pecora,Gemma Pelargonio,Saverio Iacopino,Valentino Ducceschi,Ruggero Maggio,Lorenzo Bianchini,Carmelo La Greca,Pietro Rossi,Gianluigi Bencardino,Massimo Moltrasio,Natale Di Belardino,Patrizia Pepi,Luca Rossi,Matteo Santagostino,Claudio Tondo,Antonio De Simone
DOI: https://doi.org/10.1016/j.hrthm.2024.08.040
IF: 6.779
2024-08-22
Heart Rhythm
Abstract:Background: No data have been reported on cooling characteristics and the impact of variant pulmonary vein (PV) anatomy on atrial fibrillation (AF) recurrences after POLARx cryoballoon (CB) ablation. Objective: To analyze the impact of PV anatomy variants and cooling characteristics after CB ablation from a large, multicenter, prospective registry. Methods: Primary endpoint was defined as 1-year absence of any atrial tachyarrhythmias (ATAs: AF/atrial flutter-tachycardia). Correlation between ATAs recurrences and anatomy variants/cooling characteristics were evaluated. The secondary outcome was the rate of major periprocedural complications. Results: 429 consecutive patients diagnosed with paroxysmal (83.4%) or persistent AF (peAF, 16.6%) were enrolled. Twenty-eight (6.6%) patients exhibited an anatomical variant (common ostium=4.0%, adjunctive PV=2.6%). Nadir temperature, thaw time and total deflation time were different between standard PVs and PV variants. After the blanking period, over a mean of 431±99 days of follow-up, 63 patients (14.7%) suffered an ATAs recurrence. Patients with recurrences had both a shorter thaw time (18.5±7s vs 19.8±7s, p=0.0012) and total deflation time, whereas time-to-isolation was longer (57.4±42s vs 49.1±33s, p=0.04). Patients with anatomy variants showed a similar ATAs recurrence rate (5/28, 17.9%) than the standard anatomy group (58/401, 14.5%, p=0.584; HR=1.43, CI=0.49-4.13, log-rank:p=0.4384). After adjusting for confounders, heart failure (HR=4.12, 95%CI: 1.75-9.73, p=0.0013) and peAF (HR=1.81, 95%CI: 1.03-3.18, p=0.0433) remained associated to ATAs recurrence during follow-up. Conclusion: The POLARx-CB system demonstrated long-term efficacy, along with a safe profile, in both paroxysmal and peAF patients, regardless of the presence PV variants. Time-to-isolation was longer in patients with ATAs recurrences during follow-up.